CardiNor, Bioventix, Kaivogen, and Akershus University Hospital received €631k in Eurostars funding for Secretoneurin.

CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University Hospital have been granted Eurostars funding for the project: Secretoneurin, a breakthrough blood biomarker for heart disease and sudden cardiac arrest risk.
The total funding by the EU is €631,000.
The Eurostars project will support the following important milestones for the company:
Development and optimization of a simple test for measuring SN in the blood
Clinical validation using a very comprehensive patient material, which will also support and facilitate future CE marking
Optimization of assay production that will enable rapid commercialization




